Abstract
Epoxygenase activity and synthesis of epoxyeicosatrienoic acids (EETs) have emerged as important modulators of obesity and diabetes. We examined the effect of the EET‐agonist 12‐(3‐ hexylureido)dodec‐8(2) enoic acid on Mesenchymal Stem Cell (MSC) derived adipocytes proliferation and differentiation. MSCs expressed substantial levels of EETs and inhibition of soluble Epoxide Hydrolase (sEH) increased the level of EETs and decreased adipogenesis. EET agonist treatment increased HO‐1 expression by inhibiting a negative regulator of HO‐1 expression, Bach‐1. EET treatment also increased catenin and pACC levels while decreasing PPAR C/EBP and fatty acid synthase levels. These changes were manifest by a decrease in the number of large inflammatory adipocytes, TNF, IFN and IL‐1, but an increase in small adipocytes and in adiponectin levels. In summary, EET agonist treatment inhibits adipogenesis and decreases the levels of inflammatory cytokines suggesting the potential action of EETs as intracellular lipid signaling modulators of adipogenesis and adiponectin. NIH‐ DK056601
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
